Publications
94
Citations
2,472
Est. group size
—
Recurring co-author estimate
Active years
47
Publishing since 1980
Typically publishes in teams of ~13 · 3% small-team papers (≤3 authors) · across 20 venues
- Frameworks and Strategies to Improve Inclusion of Underserved Groups in Myeloma Clinical Trials (EQUAL-ME Project): A Scoping Review Protocol
Open MIND · 2026
- Frameworks and Strategies to Improve Inclusion of Underserved Groups in Myeloma Clinical Trials (EQUAL-ME Project): A Scoping Review Protocol
Zenodo (CERN European Organization for Nuclear Research) · 2026
- Abstract 3887: Multiple myeloma risk classification of CoMMpass using Consensus Genomic Staging identifies differences between patients with high and low African genetic ancestry.
Cancer Research · 2026
- Impact of lecture on knowledge of IM residents in diagnosing and managing CRS and ICANS.
Journal of Clinical Oncology · 2026
- Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
Frontiers in Oncology · 2025
- Racial Disparities in Myeloma Care: Examining Access to Bispecific Therapies, Treatment Patterns and Outcomes among Minority Patients
Journal of the National Medical Association · 2025
- Access to CAR T-Cell Therapies in Minority Communities: A Patient Survey Study of Disparities in Multiple Myeloma Care
Journal of the National Medical Association · 2025
- Inadequate Racial Reporting among References Forming the Basis of NCCN Guidelines for Multiple Myeloma and Systemic Light Chain Amyloidosis
Clinical Lymphoma Myeloma & Leukemia · 2025
- Unpredictability of caregiver gaps in multiple myeloma: Results from a survey of >1000 patients
Blood · 2025
- The burdens associated with receiving CAR T-cell therapy: A qualitative study of CAR T patients and caregivers
Blood · 2025
- Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel
Blood Cancer Journal · 2024
- Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Blood Advances · 2024
- Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters
Seminars in Hematology · 2024
- BPI24-017: Optimizing the Implementation of New Therapies in Multiple Myeloma
Journal of the National Comprehensive Cancer Network · 2024
- Insufficient Representation and Reporting of Race in the References Forming the Basis of the National Comprehensive Cancer Network Guidelines for Multiple Myeloma
Blood · 2024
- Blood×28
- Clinical Lymphoma Myeloma & Leukemia×10
- Journal of Clinical Oncology×8
- Journal of the National Comprehensive Cancer Network×2
- Blood Cancer Journal×2
- Erica Campagnaro
Medicine · University of Michigan
- Chia‐Jen Liu
Medicine · University of Michigan
- Magdalena Czader
Medicine · Indiana University
- Jing Christine Ye
Medicine · University of Michigan
- Brian A. Walker
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile